Compile Data Set for Download or QSAR
Report error Found 90 Enz. Inhib. hit(s) with all data for entry = 10700
TargetAurora kinase A(Human)
Jacobio Pharmaceuticals

US Patent
LigandPNGBDBM560649(US11384066, Example 51 | 1-(3-chloro-2-fluorobenzy...)
Affinity DataIC50: 0.220nMAssay Description:Experimental Methods:(1) Prepare a 1× kinase buffer [50 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), PH 7.5, 0.01% Brij-35, 10 mM M...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/9/2022
Entry Details
Go to US Patent

TargetAurora kinase A(Human)
Jacobio Pharmaceuticals

US Patent
LigandPNGBDBM560627(US11384066, Example 6 | (2R,4R)-1-(3-chloro-2,6- d...)
Affinity DataIC50: 0.330nMAssay Description:Experimental Methods:(1) Prepare a 1× kinase buffer [50 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), PH 7.5, 0.01% Brij-35, 10 mM M...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/9/2022
Entry Details
Go to US Patent

TargetAurora kinase A(Human)
Jacobio Pharmaceuticals

US Patent
LigandPNGBDBM560660(US11384066, Example 78)
Affinity DataIC50: 0.370nMAssay Description:Experimental Methods:(1) Prepare a 1× kinase buffer [50 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), PH 7.5, 0.01% Brij-35, 10 mM M...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/9/2022
Entry Details
Go to US Patent

TargetAurora kinase A(Human)
Jacobio Pharmaceuticals

US Patent
LigandPNGBDBM560652(US11384066, Example 54 | 1-(2,3-dichlorobenzyl)-4-...)
Affinity DataIC50: 0.430nMAssay Description:Experimental Methods:(1) Prepare a 1× kinase buffer [50 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), PH 7.5, 0.01% Brij-35, 10 mM M...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/9/2022
Entry Details
Go to US Patent

TargetAurora kinase A(Human)
Jacobio Pharmaceuticals

US Patent
LigandPNGBDBM560648(US11384066, Example 50 | (2R,4R)-1-(3-chloro-2,6-d...)
Affinity DataIC50: 0.520nMAssay Description:Experimental Methods:(1) Prepare a 1× kinase buffer [50 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), PH 7.5, 0.01% Brij-35, 10 mM M...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/9/2022
Entry Details
Go to US Patent

TargetAurora kinase A(Human)
Jacobio Pharmaceuticals

US Patent
LigandPNGBDBM560664(US11384066, Example 90)
Affinity DataIC50: 0.540nMAssay Description:Experimental Methods:(1) Prepare a 1× kinase buffer [50 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), PH 7.5, 0.01% Brij-35, 10 mM M...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/9/2022
Entry Details
Go to US Patent

TargetAurora kinase A(Human)
Jacobio Pharmaceuticals

US Patent
LigandPNGBDBM560632(US11384066, Example 15 | (2R,4R)-1-(2,3- difluorob...)
Affinity DataIC50: 0.550nMAssay Description:Experimental Methods:(1) Prepare a 1× kinase buffer [50 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), PH 7.5, 0.01% Brij-35, 10 mM M...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/9/2022
Entry Details
Go to US Patent

TargetAurora kinase A(Human)
Jacobio Pharmaceuticals

US Patent
LigandPNGBDBM560651(US11384066, Example 53 | (2R,4R)-1-(2,3-dichloro- ...)
Affinity DataIC50: 0.550nMAssay Description:Experimental Methods:(1) Prepare a 1× kinase buffer [50 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), PH 7.5, 0.01% Brij-35, 10 mM M...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/9/2022
Entry Details
Go to US Patent

TargetAurora kinase A(Human)
Jacobio Pharmaceuticals

US Patent
LigandPNGBDBM560654(US11384066, Example 66 | 1-(3-chloro-2-fluorobenzy...)
Affinity DataIC50: 0.570nMAssay Description:Experimental Methods:(1) Prepare a 1× kinase buffer [50 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), PH 7.5, 0.01% Brij-35, 10 mM M...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/9/2022
Entry Details
Go to US Patent

TargetAurora kinase A(Human)
Jacobio Pharmaceuticals

US Patent
LigandPNGBDBM560644(US11384066, Example 39)
Affinity DataIC50: 0.570nMAssay Description:Experimental Methods:(1) Prepare a 1× kinase buffer [50 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), PH 7.5, 0.01% Brij-35, 10 mM M...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/9/2022
Entry Details
Go to US Patent

TargetAurora kinase A(Human)
Jacobio Pharmaceuticals

US Patent
LigandPNGBDBM560626(US11384066, Example 5)
Affinity DataIC50: 0.590nMAssay Description:Experimental Methods:(1) Prepare a 1× kinase buffer [50 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), PH 7.5, 0.01% Brij-35, 10 mM M...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/9/2022
Entry Details
Go to US Patent

TargetAurora kinase A(Human)
Jacobio Pharmaceuticals

US Patent
LigandPNGBDBM560661(US11384066, Example 79 | 1-(3-chloro-2-fluorobenzy...)
Affinity DataIC50: 0.610nMAssay Description:Experimental Methods:(1) Prepare a 1× kinase buffer [50 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), PH 7.5, 0.01% Brij-35, 10 mM M...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/9/2022
Entry Details
Go to US Patent

TargetAurora kinase A(Human)
Jacobio Pharmaceuticals

US Patent
LigandPNGBDBM560630(US11384066, Example 11 | (2R,4R)-1-(3-chloro-2- f...)
Affinity DataIC50: 0.640nMAssay Description:Experimental Methods:(1) Prepare a 1× kinase buffer [50 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), PH 7.5, 0.01% Brij-35, 10 mM M...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/9/2022
Entry Details
Go to US Patent

TargetAurora kinase A(Human)
Jacobio Pharmaceuticals

US Patent
LigandPNGBDBM560657(US11384066, Example 72)
Affinity DataIC50: 0.640nMAssay Description:Experimental Methods:(1) Prepare a 1× kinase buffer [50 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), PH 7.5, 0.01% Brij-35, 10 mM M...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/9/2022
Entry Details
Go to US Patent

TargetAurora kinase A(Human)
Jacobio Pharmaceuticals

US Patent
LigandPNGBDBM560659(US11384066, Example 74 | (2R,4R)-1-(3-chloro-2-flu...)
Affinity DataIC50: 0.670nMAssay Description:Experimental Methods:(1) Prepare a 1× kinase buffer [50 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), PH 7.5, 0.01% Brij-35, 10 mM M...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/9/2022
Entry Details
Go to US Patent

TargetAurora kinase A(Human)
Jacobio Pharmaceuticals

US Patent
LigandPNGBDBM560647(US11384066, Example 49)
Affinity DataIC50: 0.700nMAssay Description:Experimental Methods:(1) Prepare a 1× kinase buffer [50 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), PH 7.5, 0.01% Brij-35, 10 mM M...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/9/2022
Entry Details
Go to US Patent

TargetAurora kinase A(Human)
Jacobio Pharmaceuticals

US Patent
LigandPNGBDBM560666(US11384066, Example 92 | 1-(3-chloro-2-fluorobenzy...)
Affinity DataIC50: 0.740nMAssay Description:Experimental Methods:(1) Prepare a 1× kinase buffer [50 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), PH 7.5, 0.01% Brij-35, 10 mM M...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/9/2022
Entry Details
Go to US Patent

TargetAurora kinase A(Human)
Jacobio Pharmaceuticals

US Patent
LigandPNGBDBM560658(US11384066, Example 73 | (2R,4R)-1-(3-chloro-2-flu...)
Affinity DataIC50: 0.760nMAssay Description:Experimental Methods:(1) Prepare a 1× kinase buffer [50 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), PH 7.5, 0.01% Brij-35, 10 mM M...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/9/2022
Entry Details
Go to US Patent

TargetAurora kinase A(Human)
Jacobio Pharmaceuticals

US Patent
LigandPNGBDBM560662(US11384066, Example 81 | (2R,4R)-1-(3-chloro-2-flu...)
Affinity DataIC50: 0.770nMAssay Description:Experimental Methods:(1) Prepare a 1× kinase buffer [50 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), PH 7.5, 0.01% Brij-35, 10 mM M...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/9/2022
Entry Details
Go to US Patent

TargetAurora kinase A(Human)
Jacobio Pharmaceuticals

US Patent
LigandPNGBDBM560638(US11384066, Example 27 | (2R,4R)-1-(3-chloro-2,4- ...)
Affinity DataIC50: 0.810nMAssay Description:Experimental Methods:(1) Prepare a 1× kinase buffer [50 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), PH 7.5, 0.01% Brij-35, 10 mM M...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/9/2022
Entry Details
Go to US Patent

TargetAurora kinase A(Human)
Jacobio Pharmaceuticals

US Patent
LigandPNGBDBM560643(US11384066, Example 38 | (2R,4R)-1-(2-(3-chloro-2-...)
Affinity DataIC50: 0.850nMAssay Description:Experimental Methods:(1) Prepare a 1× kinase buffer [50 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), PH 7.5, 0.01% Brij-35, 10 mM M...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/9/2022
Entry Details
Go to US Patent

TargetAurora kinase A(Human)
Jacobio Pharmaceuticals

US Patent
LigandPNGBDBM560646(US11384066, Example 45)
Affinity DataIC50: 0.880nMAssay Description:Experimental Methods:(1) Prepare a 1× kinase buffer [50 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), PH 7.5, 0.01% Brij-35, 10 mM M...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/9/2022
Entry Details
Go to US Patent

TargetAurora kinase A(Human)
Jacobio Pharmaceuticals

US Patent
LigandPNGBDBM560653(US11384066, Example 55 | 1-(3-chloro-2,6-difluoro-...)
Affinity DataIC50: 0.880nMAssay Description:Experimental Methods:(1) Prepare a 1× kinase buffer [50 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), PH 7.5, 0.01% Brij-35, 10 mM M...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/9/2022
Entry Details
Go to US Patent

TargetAurora kinase A(Human)
Jacobio Pharmaceuticals

US Patent
LigandPNGBDBM560656(US11384066, Example 69 | 4-((4-acetyl-3-fluoro-6-(...)
Affinity DataIC50: 0.910nMAssay Description:Experimental Methods:(1) Prepare a 1× kinase buffer [50 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), PH 7.5, 0.01% Brij-35, 10 mM M...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/9/2022
Entry Details
Go to US Patent

TargetAurora kinase A(Human)
Jacobio Pharmaceuticals

US Patent
LigandPNGBDBM560636(US11384066, Example 23 | (2R,4R)-1-(3,5-dichloro- ...)
Affinity DataIC50: 0.910nMAssay Description:Experimental Methods:(1) Prepare a 1× kinase buffer [50 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), PH 7.5, 0.01% Brij-35, 10 mM M...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/9/2022
Entry Details
Go to US Patent

TargetAurora kinase A(Human)
Jacobio Pharmaceuticals

US Patent
LigandPNGBDBM560667(US11384066, Example 102)
Affinity DataIC50: 0.930nMAssay Description:Experimental Methods:(1) Prepare a 1× kinase buffer [50 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), PH 7.5, 0.01% Brij-35, 10 mM M...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/9/2022
Entry Details
Go to US Patent

TargetAurora kinase A(Human)
Jacobio Pharmaceuticals

US Patent
LigandPNGBDBM560629(US11384066, Example 10 | (2R,4R)-1-(3-chloro-2- fl...)
Affinity DataIC50: 1nMAssay Description:Experimental Methods:(1) Prepare a 1× kinase buffer [50 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), PH 7.5, 0.01% Brij-35, 10 mM M...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/9/2022
Entry Details
Go to US Patent

TargetAurora kinase A(Human)
Jacobio Pharmaceuticals

US Patent
LigandPNGBDBM560668(US11384066, Example LY3295668)
Affinity DataIC50: 1nMAssay Description:Experimental Methods:(1) Prepare a 1× kinase buffer [50 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), PH 7.5, 0.01% Brij-35, 10 mM M...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/9/2022
Entry Details
Go to US Patent
PDB3D3D Structure (crystal)
TargetAurora kinase A(Human)
Jacobio Pharmaceuticals

US Patent
LigandPNGBDBM560665(US11384066, Example 91)
Affinity DataIC50: 1.10nMAssay Description:Experimental Methods:(1) Prepare a 1× kinase buffer [50 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), PH 7.5, 0.01% Brij-35, 10 mM M...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/9/2022
Entry Details
Go to US Patent

TargetAurora kinase A(Human)
Jacobio Pharmaceuticals

US Patent
LigandPNGBDBM560640(US11384066, Example 30 | (2R,4R)-1-(3-chloro-2- fl...)
Affinity DataIC50: 1.10nMAssay Description:Experimental Methods:(1) Prepare a 1× kinase buffer [50 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), PH 7.5, 0.01% Brij-35, 10 mM M...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/9/2022
Entry Details
Go to US Patent

TargetAurora kinase A(Human)
Jacobio Pharmaceuticals

US Patent
LigandPNGBDBM560628(US11384066, Example 8 | (2R,4R)-1-(3-chloro-2- flu...)
Affinity DataIC50: 1.20nMAssay Description:Experimental Methods:(1) Prepare a 1× kinase buffer [50 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), PH 7.5, 0.01% Brij-35, 10 mM M...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/9/2022
Entry Details
Go to US Patent

TargetAurora kinase A(Human)
Jacobio Pharmaceuticals

US Patent
LigandPNGBDBM560624(US11384066, Example 1)
Affinity DataIC50: 1.30nMAssay Description:Experimental Methods:(1) Prepare a 1× kinase buffer [50 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), PH 7.5, 0.01% Brij-35, 10 mM M...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/9/2022
Entry Details
Go to US Patent

TargetAurora kinase A(Human)
Jacobio Pharmaceuticals

US Patent
LigandPNGBDBM560650(US11384066, Example 52 | 1-(2,3-difluorobenzyl)-4-...)
Affinity DataIC50: 1.30nMAssay Description:Experimental Methods:(1) Prepare a 1× kinase buffer [50 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), PH 7.5, 0.01% Brij-35, 10 mM M...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/9/2022
Entry Details
Go to US Patent

TargetAurora kinase A(Human)
Jacobio Pharmaceuticals

US Patent
LigandPNGBDBM560663(US11384066, Example 84)
Affinity DataIC50: 1.40nMAssay Description:Experimental Methods:(1) Prepare a 1× kinase buffer [50 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), PH 7.5, 0.01% Brij-35, 10 mM M...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/9/2022
Entry Details
Go to US Patent

TargetAurora kinase A(Human)
Jacobio Pharmaceuticals

US Patent
LigandPNGBDBM560639(US11384066, Example 29 | (2R,4R)-1-(3-chloro-2- fl...)
Affinity DataIC50: 1.40nMAssay Description:Experimental Methods:(1) Prepare a 1× kinase buffer [50 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), PH 7.5, 0.01% Brij-35, 10 mM M...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/9/2022
Entry Details
Go to US Patent

TargetAurora kinase A(Human)
Jacobio Pharmaceuticals

US Patent
LigandPNGBDBM560641(US11384066, Example 33 | (2R,4R)-1-(3-chloro-2- fl...)
Affinity DataIC50: 1.5nMAssay Description:Experimental Methods:(1) Prepare a 1× kinase buffer [50 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), PH 7.5, 0.01% Brij-35, 10 mM M...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/9/2022
Entry Details
Go to US Patent

TargetAurora kinase A(Human)
Jacobio Pharmaceuticals

US Patent
LigandPNGBDBM560655(US11384066, Example 67)
Affinity DataIC50: 1.60nMAssay Description:Experimental Methods:(1) Prepare a 1× kinase buffer [50 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), PH 7.5, 0.01% Brij-35, 10 mM M...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/9/2022
Entry Details
Go to US Patent

TargetAurora kinase A(Human)
Jacobio Pharmaceuticals

US Patent
LigandPNGBDBM560633(US11384066, Example 16 | (2R,4R)-1-(2-fluoro-3- m...)
Affinity DataIC50: 1.70nMAssay Description:Experimental Methods:(1) Prepare a 1× kinase buffer [50 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), PH 7.5, 0.01% Brij-35, 10 mM M...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/9/2022
Entry Details
Go to US Patent

TargetAurora kinase A(Human)
Jacobio Pharmaceuticals

US Patent
LigandPNGBDBM560642(US11384066, Example 35 | (2R,4R)-1-(3-chloro-2- fl...)
Affinity DataIC50: 1.90nMAssay Description:Experimental Methods:(1) Prepare a 1× kinase buffer [50 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), PH 7.5, 0.01% Brij-35, 10 mM M...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/9/2022
Entry Details
Go to US Patent

TargetAurora kinase A(Human)
Jacobio Pharmaceuticals

US Patent
LigandPNGBDBM560631(US11384066, Example 12 | (2R,4R)-1-(2,6- difluorob...)
Affinity DataIC50: 2.40nMAssay Description:Experimental Methods:(1) Prepare a 1× kinase buffer [50 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), PH 7.5, 0.01% Brij-35, 10 mM M...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/9/2022
Entry Details
Go to US Patent

TargetAurora kinase A(Human)
Jacobio Pharmaceuticals

US Patent
LigandPNGBDBM560645(US11384066, Example 41)
Affinity DataIC50: 2.70nMAssay Description:Experimental Methods:(1) Prepare a 1× kinase buffer [50 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), PH 7.5, 0.01% Brij-35, 10 mM M...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/9/2022
Entry Details
Go to US Patent

TargetAurora kinase A(Human)
Jacobio Pharmaceuticals

US Patent
LigandPNGBDBM560625(US11384066, Example 2)
Affinity DataIC50: 2.90nMAssay Description:Experimental Methods:(1) Prepare a 1× kinase buffer [50 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), PH 7.5, 0.01% Brij-35, 10 mM M...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/9/2022
Entry Details
Go to US Patent

TargetAurora kinase A(Human)
Jacobio Pharmaceuticals

US Patent
LigandPNGBDBM560637(US11384066, Example 26 | (2R,4R)-1-(3-chloro-2- fl...)
Affinity DataIC50: 2.90nMAssay Description:Experimental Methods:(1) Prepare a 1× kinase buffer [50 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), PH 7.5, 0.01% Brij-35, 10 mM M...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/9/2022
Entry Details
Go to US Patent

TargetAurora kinase A(Human)
Jacobio Pharmaceuticals

US Patent
LigandPNGBDBM560635(US11384066, Example 21 | (2R,4R)-4-((3-fluoro-6- (...)
Affinity DataIC50: 3.10nMAssay Description:Experimental Methods:(1) Prepare a 1× kinase buffer [50 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), PH 7.5, 0.01% Brij-35, 10 mM M...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/9/2022
Entry Details
Go to US Patent

TargetAurora kinase A(Human)
Jacobio Pharmaceuticals

US Patent
LigandPNGBDBM560634(US11384066, Example 17 | (2R,4R)-1-(2,6- dichlorob...)
Affinity DataIC50: 3.20nMAssay Description:Experimental Methods:(1) Prepare a 1× kinase buffer [50 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), PH 7.5, 0.01% Brij-35, 10 mM M...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/9/2022
Entry Details
Go to US Patent

TargetAurora kinase B(Human)
Jacobio Pharmaceuticals

US Patent
LigandPNGBDBM560651(US11384066, Example 53 | (2R,4R)-1-(2,3-dichloro- ...)
Affinity DataIC50: 309nMAssay Description:Experimental Methods:(1) Prepare a 1× kinase buffer [50 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), PH 7.5, 0.01% Brij-35, 10 mM M...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/9/2022
Entry Details
Go to US Patent

TargetAurora kinase B(Human)
Jacobio Pharmaceuticals

US Patent
LigandPNGBDBM560647(US11384066, Example 49)
Affinity DataIC50: 310nMAssay Description:Experimental Methods:(1) Prepare a 1× kinase buffer [50 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), PH 7.5, 0.01% Brij-35, 10 mM M...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/9/2022
Entry Details
Go to US Patent

TargetAurora kinase B(Human)
Jacobio Pharmaceuticals

US Patent
LigandPNGBDBM560657(US11384066, Example 72)
Affinity DataIC50: 372nMAssay Description:Experimental Methods:(1) Prepare a 1× kinase buffer [50 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), PH 7.5, 0.01% Brij-35, 10 mM M...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/9/2022
Entry Details
Go to US Patent

TargetAurora kinase B(Human)
Jacobio Pharmaceuticals

US Patent
LigandPNGBDBM560654(US11384066, Example 66 | 1-(3-chloro-2-fluorobenzy...)
Affinity DataIC50: 408nMAssay Description:Experimental Methods:(1) Prepare a 1× kinase buffer [50 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), PH 7.5, 0.01% Brij-35, 10 mM M...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/9/2022
Entry Details
Go to US Patent

TargetAurora kinase B(Human)
Jacobio Pharmaceuticals

US Patent
LigandPNGBDBM560648(US11384066, Example 50 | (2R,4R)-1-(3-chloro-2,6-d...)
Affinity DataIC50: 439nMAssay Description:Experimental Methods:(1) Prepare a 1× kinase buffer [50 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), PH 7.5, 0.01% Brij-35, 10 mM M...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/9/2022
Entry Details
Go to US Patent

Displayed 1 to 50 (of 90 total ) | Next | Last >>
Jump to: